Navigation Links
Phytomedics Inc. To Present at BIO 2010 International Convention
Date:4/28/2010

JAMESBURG, N.J., April 28 /PRNewswire/ -- Phytomedics Inc., a clinical stage biopharmaceutical company developing a novel portfolio of drugs and consumer products solely derived from plant sources, today announced that Dr. Laurie Smaldone, MD, President and Chief Executive Officer, will deliver a corporate presentation at the BIO 2010 International Convention on Thursday, May 6th, at McCormick Place Convention Center in Chicago.

Dr. Smaldone's presentation will take place at 9:30 a.m. CDT in Presentation Room D, as part of the 2010 BIO Business Forum.

Her presentation will provide a corporate overview and highlight the clinical progress of the company's lead drug candidate, PMI-001, a novel, oral, disease-modifying, non-steroidal, natural product alternative to injectable biologicals in patients with RA.

Three U.S. based, FDA-approved clinical trials, have confirmed biological like efficacy of this botanical drug candidate as a stand-alone therapy in reducing signs and symptoms of RA at all American College of Rheumatology (ACR) endpoints,  a rapid onset of action and, the ability to halt joint erosions and narrowing with an acceptable side effect profile.  Combined with the fact that this natural botanical drug product is delivered as an oral dosage form, and has no steroid like side effects, makes PMI-001 truly is a game changing therapeutic opportunity in RA, as well as in the wider AA space.

About Phytomedics Inc.

Phytomedics, Inc. is a clinical stage biopharmaceutical company with a novel portfolio of drugs and consumer products solely derived from plant sources. Through this proprietary technology platform, the Company has produced a broad pipeline of lead product candidates, several of which are in clinical development.  The company's lead candidate, PMI-001, is a novel, oral, disease modifying anti-rheumatic drug currently being developed as a natural pharmaceutical alternative in rheumatoid arthritis therapy. Founded by Professor Ilya Raskin, Ph.D., presently the company's Chief Scientific Officer, Phytomedics Inc. conducts most of its discovery activities at the Biotech Center of Rutgers University.


'/>"/>
SOURCE Phytomedics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
9. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
10. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
11. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... PUNE, India , May 26, 2016 ... pain drugs market growth is the emergence of new ... developing astaxanthin therapies for osteoarthritis treatment. The therapy is ... market. Moreover, Arthritis Research UK is conducting studies to ... the arcOGEN study, where the genes involved in osteoarthritis ...
(Date:5/25/2016)... India , May 25, 2016 ... Animation Market by Type (3D, 2D, 4D), by Therapeutic ... Education), by End User (Medical Device Manufacturers, Hospitals/ Clinics) ... studies the global Medical Animation Market for the forecast ... to reach USD 301.3 Million by 2021 from USD ...
(Date:5/25/2016)... , May 25, 2016 According ... Share, Development, Growth and Demand Forecast to 2022 - ... Pump and Others)" published by P&S Market Research, the ... million in 2015, and it is expected to grow ... type, the insulin pump segment is expected to witness ...
Breaking Medicine Technology:
(Date:5/29/2016)... (PRWEB) , ... May 29, 2016 , ... Whole Health ... Amazon.com, their new KlipPro KP-240L clipper is available to the public. This is an ... is substantially wider than the average clipper. , Everything about this product is concentrated ...
(Date:5/28/2016)... CT (PRWEB) , ... May 28, 2016 , ... After a year and a half ... it was an extraordinary event. The Multiple Pathways of Recovery Conference was held May ... across the country and the United Kingdom came together to explore the many pathways individuals ...
(Date:5/27/2016)... ... May 27, 2016 , ... W.S. Badger Co. Inc ., the maker ... been recognized as one of the best small businesses for new dads by Fatherly, ... nine small businesses providing progressive benefits to new parents on the organization’s 2016 ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... help educate the many who are unaware of the plight of aphasia. In ... run within the “Stroke Awareness” campaign. , The link between stroke and aphasia ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... the pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center ... proof of successfully certified products, services and staff. , Validation Center is ISO17025 ...
Breaking Medicine News(10 mins):